SAR: SDC-1801 advanced toward Phase 2 readiness, backed by ~£3.3m in post-period funding

Less than 1 min read

SDC-1801 completed toxicology dosing and is targeted for Phase 2 readiness by mid-2027. Post-period fundraising of ~£3.3m supports the programme and neuroscience work; FY2026 loss after tax was £3.263m.

Original document: [Sareum Holdings plc [SAR] Annual Financial Statement — Nov. 3 2026](https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Areport%3Aquartr.com%3A3684050-5067443a97fc582ba3b00b915d2b456e)

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.